Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's Desano Pharma to Make API for New HIV Drug for ViiV

publication date: Jul 2, 2015
Desano Pharmaceuticals of Shanghai struck a deal with ViiV Healthcare to produce the active ingredient of GlaxoSmithKline's new HIV drug, dolutegravir, an integrase strand transfer inhibitor. ViiV was formed in 2009 by GSK and Pfizer to offer cost-effective HIV treatments to less-developed countries. Shionogi joined in 2012. By outsourcing the production of the API to Desano, ViiV can lower the cost. ViiV intends to combine dolutegravir with anti-retrovirals to make the combination therapy Tivicay. More details....

Stock Symbols: (NYSE: GSK) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital